PATH EX
Nashville
About PATH EX
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EX is taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $9.8M
- Last round: Series Unknown (May 2025)
- Website: pathex.co
- Phone: (412)496-7066
Industries & Categories
Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/path-ex-20545 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.